Data, Epilepsy, Media and Treatment - Medical Cannabis Brief

PA: Court orders release on medical cannabis data regarding, “how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment.”

Cannabis Law Report

AUGUST 23, 2022

A panel of Commonwealth Court judges has ordered the Wolf administration to reveal how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment. Qualifying conditions include anxiety disorders, severe chronic pain and epilepsy.

Data

Data Treatment Patients Chronic Pain

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8

Epilepsy

Epilepsy Pharmaceutical Patients Sleep

CBD Market Report

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.

CBD

CBD Seed-To-Sale Food Access

Specialist Doctors Launch Sapphire Medical Clinic, UK’s First Medicinal Cannabis Clinic to Treat Full Range of Health Issues Including Childhood Epilepsy

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy

Epilepsy Medicine Treatment Patients

Renewing Medical Marijuana Cards in Arkansas: All You Need to Know

MMJ Recs

MAY 3, 2024

With its program in full swing, thousands of patients across the state are benefiting from access to this alternative form of treatment. From chronic pain to PTSD, patients with qualifying medical conditions have found solace in medical marijuana where traditional treatments may have fallen short.

Marijuana

Marijuana Treatment Compliance Compliance

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical

Pharmaceutical Epilepsy Research and Development Medicine

Texas Original Advocates To Expand Compassionate Use Program To Include Chronic Pain

Cannabis Law Report

SEPTEMBER 1, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. 1 reason patients seek medical cannabis is to augment their pain management treatment.

Chronic Pain

Chronic Pain Programs Patients Conditions

Texas Original Advocates To Expand Compassionate Use Program To Include Chronic Pain

Cannabis Law Report

AUGUST 31, 2022

The CUP’s current list of qualifying conditions includes cancer, PTSD, epilepsy and hundreds of neurodegenerative diseases but excludes the many other patients who could benefit from the proven power of medical cannabis to treat chronic pain. 1 reason patients seek medical cannabis is to augment their pain management treatment.

Chronic Pain

Chronic Pain Programs Patients Conditions

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia.

Pharmaceutical

Pharmaceutical Clinical Trials Research and Development Programs

Marijuana & COVID-19: Top Studies [August 2020]

CannaMD

AUGUST 19, 2020

Unlike THC, CBD has a high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity. .” Our initial data suggest that some C.

Research and Development

Research and Development Marijuana Extraction Terpenes

FDA Warns Companies Allegedly Illegally Selling CBD and Delta-8 THC Products to Label and Brand More Carefully

Cannabis Law Report

MAY 6, 2022

The FDA’s warning letters tell the public that the FDA reads and reviews companies’ websites, labels, social media, and marketing language. The FDA evaluates sellers’ claims, graphics, and product descriptions – including products marketed for animals, information about food additives, and social media websites.

THC

THC CBD Media Food

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders. Media: media@mymd.com.

Clinical Trials

Clinical Trials Pharmaceutical Research and Development Therapy

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy. Background. Cancer pain.

Research and Development

Research and Development Medicine Access Media

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Media: Laura Radocaj.

Clinical Trials

Clinical Trials Chronic Pain Pharmaceutical Topical

FDA Press Release: FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns

Cannabis Law Report

NOVEMBER 26, 2019

Many unanswered questions and data gaps about CBD toxicity exist, and some of the available data raise serious concerns about potential harm from CBD. The FDA has not approved any CBD products other than one prescription human drug product to treat rare, severe forms of epilepsy.

Safety

Safety Food CBD Oil

FDA Public Hearing on Regulatory Pathway for CBD to Take Place on May 31st in Washington DC

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD

CBD Research and Development Safety Therapy

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. Email: alexander.speiser@eleusisltd.com.

Therapy

Therapy Research and Development Business Access

Medical Cannabis Brief

PA: Court orders release on medical cannabis data regarding, “how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment.”

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Trending Sources

CBD Market Report

Specialist Doctors Launch Sapphire Medical Clinic, UK’s First Medicinal Cannabis Clinic to Treat Full Range of Health Issues Including Childhood Epilepsy

Renewing Medical Marijuana Cards in Arkansas: All You Need to Know

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Texas Original Advocates To Expand Compassionate Use Program To Include Chronic Pain

Texas Original Advocates To Expand Compassionate Use Program To Include Chronic Pain

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Marijuana & COVID-19: Top Studies [August 2020]

FDA Warns Companies Allegedly Illegally Selling CBD and Delta-8 THC Products to Label and Brand More Carefully

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

FDA Press Release: FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns

FDA Public Hearing on Regulatory Pathway for CBD to Take Place on May 31st in Washington DC

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Stay Connected